29 Results

People

  1. Stein
    Stein
  2. Tallman
    Tallman
  3. Bewersdorf
    Bewersdorf
  4. Levine
    Levine
  5. Rampal
    Rampal
  6. Shih
    Shih
  7. Derkach
    Derkach
  8. Goldberg
    Goldberg
  9. Intlekofer
    Intlekofer
  10. Papaemmanuil
    Papaemmanuil

Groups

  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Hematologic Malignancies, Division of (25)
  4. Adult Leukemia (24)
  5. Hematology-Oncology Fellows (7)
  6. GME, Medicine (5)
  7. Graduate Medical Education (5)
  8. Weinberg Fellows (5)
  9. Epidemiology and Biostatistics (4)
  10. Department of Pathology and Laboratory Medicine (3)
  1. "enasidenib"
Formats
  1. Journal Article (17)
  2. Review (8)
  3. Editorial (1)
  4. Meeting Abstract (1)
  5. Miscellaneous (1)
  6. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Hematologic Malignancies, Division of (25)
  4. Adult Leukemia (24)
  5. Hematology-Oncology Fellows (7)
  6. GME, Medicine (5)

More Groups

People
  1. Eytan Stein (18)
  2. Martin Tallman (7)
  3. Jan Bewersdorf (4)
  4. Alan Shih (3)
  5. Raajit Rampal (3)
  6. Ross Levine (3)

More People

Years
  1. 2025 (2)
  2. 2024 (4)
  3. 2023 (4)
  4. 2022 (4)
  5. 2021 (2)
  6. 2020 (3)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (3)
  2. Leukemia and Lymphoma (3)
  3. Blood (2)
  4. Blood Advances (2)
  5. Acta Haematologica (1)
  6. Blood Reviews (1)

More Publications

Publishers
  1. American Society of Hematology (5)
  2. Elsevier Inc. (3)
  3. Taylor & Francis Group (3)
  4. John Wiley & Sons (2)
  5. Wiley Blackwell (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (29)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML
    Journal Article

    Alhajahjeh, A.; Patel, K. K.; Shallis, R. M.; Podoltsev, N. A.; Kewan, T.; Stempel, J. M.; Mendez, L.; Huntington, S. F.; Stahl, M.; Goshua, G.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Acute myeloid leukemia management and research in 2025
    Review

    Kantarjian, H. M.; DiNardo, C. D.; Kadia, T. M.; Daver, N. G.; Altman, J. K.; Stein, E. M.; Jabbour, E.; Schiffer, C. A.; Lang, A.; Ravandi, F.
    CA - A Cancer Journal for Clinicians (2025)

    Fulltext@MSK | Save
  • Beyond HMAs: Novel targets and therapeutic approaches
    Review

    Getz, T. M.; Bewersdorf, J. P.; Kewan, T.; Stempel, J. M.; Bidikian, A.; Shallis, R. M.; Stahl, M.; Zeidan, A. M.
    Seminars in Hematology (2024)

    Fulltext@MSK | Save
  • Acute febrile neutrophilic dermatosis (sweet syndrome) in acute myeloid leukemia patients: A 28-year institutional experience
    Journal Article

    Cowen, E. A.; Barrios, D. M.; Pulitzer, M. P.; Moy, A. P.; Dusza, S. W.; De Wolf, S.; Geyer, M. B.; Markova, A.
    Acta Haematologica (2024)

    Fulltext@MSK | Save
  • Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: Pooled analysis from clinical trials
    Journal Article

    Montesinos, P.; Fathi, A. T.; de Botton, S.; Stein, E. M.; Zeidan, A. M.; Zhu, Y.; Prebet, T.; Vigil, C. E.; Bluemmert, I.; Yu, X.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Transplantation and cellular therapy for older adults—The MSK approach
    Review

    Lin, R. J.; Dahi, P. B.; Korc-Grodzicki, B.; Shahrokni, A.; Jakubowski, A. A.; Giralt, S. A.
    Current Hematologic Malignancy Reports (2024)

    Fulltext@MSK | Save
  • IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: A multicentre experience
    Research Letter

    Gangat, N.; Ajufo, H.; Abdelmagid, M.; Karrar, O.; McCullough, K.; Badar, T.; Foran, J.; Palmer, J.; Alkhateeb, H.; Mangaonkar, A.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • What’s next after hypomethylating agents failure in myeloid neoplasms? A rational approach
    Review

    Awada, H.; Gurnari, C.; Xie, Z.; Bewersdorf, J. P.; Zeidan, A. M.
    Cancers (2023)

    Fulltext@MSK | Save
  • Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
    Journal Article

    Bewersdorf, J. P.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • IDH2 inhibition in AML
    Editorial

    Stein, E. M.
    Blood (2023)

    Fulltext@MSK | Save